Please check your internet connection and try again.
## Sodium Phosphate Enema
### Overview
Sodium phosphate enema is a hypertonic saline solution used as a stimulant laxative to promote bowel evacuation.
### Primary Indications
* Bowel preparation prior to colonoscopy or surgery.
* Relief of occasional constipation.
### Adult Dosing
* **Bowel Preparation:** Typically one 4.5 oz (133 mL) enema administered 3-5 hours prior to the procedure. May be repeated if necessary and directed by the prescribing provider.
* **Constipation:** One 4.5 oz (133 mL) enema, administered no more frequently than once daily or as directed.
### Pediatric Dosing
* **Age 2-11 years:** One 2.25 oz (66 mL) enema administered 3-5 hours prior to the procedure or as directed.
* **Age < 2 years:** Use is generally not recommended due to risk of severe electrolyte abnormalities. Consult with a pediatric specialist for alternative agents or carefully considered use under strict supervision.
### Dose Adjustments
* No specific dose adjustments are typically required based on renal or hepatic impairment, but caution is advised due to potential for electrolyte disturbances.
### Contraindications
* Congestive heart failure.
* Newly diagnosed or moderate-to-severe renal impairment.
* Congenital megacolon.
* Anuria.
* Patients on medications that may affect renal function (e.g., diuretics, ACE inhibitors, ARBs, NSAIDs) when used for bowel preparation.
* Hypersensitivity to sodium phosphate.
* Ileus or bowel obstruction.
* Children under 2 years of age.
### Adverse Effects
* **Common:** Abdominal cramping, nausea, vomiting, bloating, rectal irritation.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, metabolic acidosis, dehydration, renal tubular damage, seizures, cardiac arrhythmias, severe gastrointestinal distress, and death (particularly in children and those with underlying renal impairment or dehydration).
### Key Drug Interactions
* **Diuretics, ACE Inhibitors, ARBs, NSAIDs:** Increased risk of renal impairment and electrolyte disturbances, especially with concurrent use for bowel preparation.
* **Calcium-containing medications, Aluminum-containing antacids:** May increase the risk of hyperphosphatemia.
### Monitoring
* Monitor for signs and symptoms of dehydration and electrolyte imbalance (e.g., thirst, dry mouth, decreased urine output, dizziness, muscle cramps, lethargy, confusion).
* Electrolyte levels (phosphate, calcium, sodium, potassium) may be considered in high-risk patients or if symptoms arise.
* Renal function may be monitored in patients with pre-existing renal disease or risk factors.
### Clinical Pearls
* Ensure adequate hydration before and after administration.
* Patient education is crucial regarding correct administration technique and potential adverse effects.
* Avoid concurrent use with other phosphate-containing products.
* Due to the risk of serious complications, especially in pediatric patients and those with renal insufficiency, alternative bowel preparation methods may be preferred in these populations. The FDA has issued warnings regarding the use of oral and rectal sodium phosphate preparations.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace current prescribing information or clinical judgment. Always verify information with the most current drug labeling and institutional protocols.*
